Antitubulins, like taxanes, are the most widely used and effective agents in human oncology. Unfortunately, antitubulins have major limitations in canine oncology care: intravenous route of administration, high rates of severe hypersensitivity reactions to the Cremophor EL solvent, and dose limiting toxicities of severe febrile neutropenia and sepsis. VERU-111 is an oral antitubulin that targets both alpha and beta tubulin subunits of microtubules and could have an important role against canine malignancies. Based on safety studies in dogs, VERU-111 has high oral bioavailability without the hypersensitivity, neurotoxicity and neutropenia dose limiting toxicities typical of taxanes. Preclinical in vitro cell line studies show that VERU-111 has activity against many of the common canine tumors including mast cell tumor, hemangiosarcoma, osteosarcoma, and lymphoid malignancies. A Phase 1 study is currently being planned in dogs with a variety of metastatic cancers. Oral antitubulin VERU-111 could be an important new addition to the armamentarium against canine cancers: ability for home administration and dose changes with efficacy against a broad range of cancer types and a better safety profile.